Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chemotherapy Induced Neutropenia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Chemotherapy Induced Neutropenia - Pipeline Review, H1 2016', provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia - The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects - The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Chemotherapy Induced Neutropenia Overview 10 Therapeutics Development 11 Pipeline Products for Chemotherapy Induced Neutropenia - Overview 11 Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis 12 Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies 13 Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes 15 Chemotherapy Induced Neutropenia - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Chemotherapy Induced Neutropenia - Products under Development by Companies 20 Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes 22 Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 23 Apotex Inc. 23 Biogenomics Limited 24 Bolder Biotechnology, Inc. 25 Cellerant Therapeutics, Inc. 26 Chong Kun Dang Pharmaceutical Corp. 27 Cinfa Biotech S.L. 28 Dr. Reddy's Laboratories Limited 29 Generon (Shanghai) Corporation Ltd. 30 Genexine, Inc. 31 Hanmi Pharmaceuticals, Co. Ltd. 32 Myelo Therapeutics GmbH 33 Octapharma AG 34 Pfenex Inc. 35 Pfizer Inc. 36 PharmaEssentia Corporation 37 Reliance Life Sciences Pvt. Ltd. 38 Richter Gedeon Nyrt. 39 Sandoz International GmbH 40 UAB Profarma 41 USV Limited 42 Chemotherapy Induced Neutropenia - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 BBT-007 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 BBT-015 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 BBT-018 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 EC-18 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 eflapegrastim - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 F-627 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 filgrastim - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 filgrastim - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 filgrastim - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 filgrastim - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 filgrastim - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 filgrastim - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 GW-003 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 GXG-3 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 HSA-GCSF - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Myelo-001 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 pegfilgrastim - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 pegfilgrastim - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 pegfilgrastim - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 pegfilgrastim - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 pegfilgrastim - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 pegfilgrastim - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 pegfilgrastim - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 pegfilgrastim - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 pegfilgrastim - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 pegfilgrastim - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 pegfilgrastim - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 pegfilgrastim - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 pegfilgrastim - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 romyelocel-L - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 TXA-302 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 WBI-2100 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Chemotherapy Induced Neutropenia - Recent Pipeline Updates 86 Chemotherapy Induced Neutropenia - Dormant Projects 93 Chemotherapy Induced Neutropenia - Discontinued Products 95 Chemotherapy Induced Neutropenia - Product Development Milestones 96 Featured News & Press Releases 96 Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 96 Dec 16, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer 96 Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 97 Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 99 May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 99 Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 100 Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 100 May 10, 2011: Dr Reddy's Launches Pegfilgrastim In India Under Brand Name Peg-grafeel 101 Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients 101 Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology 102 Appendix 103 Methodology 103 Coverage 103 Secondary Research 103 Primary Research 103 Expert Panel Validation 103 Contact Us 103 Disclaimer 104
List of Tables Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2016 11 Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Comparative Analysis by Unknown Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2016 22 Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc., H1 2016 23 Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H1 2016 24 Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H1 2016 25 Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H1 2016 26 Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 27 Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech S.L., H1 2016 28 Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 29 Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2016 30 Chemotherapy Induced Neutropenia - Pipeline by Genexine, Inc., H1 2016 31 Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 32 Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H1 2016 33 Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H1 2016 34 Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc., H1 2016 35 Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc., H1 2016 36 Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corporation, H1 2016 37 Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2016 38 Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2016 39 Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2016 40 Chemotherapy Induced Neutropenia - Pipeline by UAB Profarma, H1 2016 41 Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H1 2016 42 Assessment by Monotherapy Products, H1 2016 43 Number of Products by Stage and Target, H1 2016 45 Number of Products by Stage and Mechanism of Action, H1 2016 47 Number of Products by Stage and Route of Administration, H1 2016 49 Number of Products by Stage and Molecule Type, H1 2016 51 Chemotherapy Induced Neutropenia Therapeutics - Recent Pipeline Updates, H1 2016 86 Chemotherapy Induced Neutropenia - Dormant Projects, H1 2016 93 Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H1 2016 94 Chemotherapy Induced Neutropenia - Discontinued Products, H1 2016 95
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.